Content and data provided by various third parties and Fidelity - Terms of Use
Print.Print
Small font size A Larger text size A Largest text size A

BioMarin Pharmaceutical Plans $850 Million Notes Offering, Lines Up $2 Billion Syndicated Loan

BY MT Newswires | CORPORATE | 01/26/26 08:17 AM EST

08:17 AM EST, 01/26/2026 (MT Newswires) -- BioMarin Pharmaceutical (BMRN) said Monday that it plans to launch an $850 million offering of senior unsecured notes due 2034.

The company said it has also launched the syndication of a new $2 billion senior secured term loan B facility in connection with the pending acquisition of Amicus Therapeutics. This is in addition to a $800 million senior secured term loan, and a $600 million senior secured revolving credit facility, the company said.

BioMarin said it will use the net proceeds from the offering, the term facilities, and cash on hand to fund the acquisition and pay related fees and expenses. It also said it may borrow up to $150 million under the new revolving facility to pay the fees and expenses.

Shares of the biotech firm were down more than 3% pre-bell Monday.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

More Fixed Income News

All Fixed Income News

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

© 1998 – 2014 FMR LLC.

All rights reserved.
fir_news_article